Comparison between the clinical efficacy of linagliptin and sitagliptin

Comparison between the clinical efficacy of linagliptin and sitagliptin - Comparison between the clinical efficacy of linagliptin and sitagliptin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010998

Enrollment

Registered

2013-06-19

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

linagliptin sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Type 2 diabetes, in whom pharmacological treatment was recently initiated at our hospital

Exclusion criteria

Exclusion criteria: 1. < 20 year-old or 80 year old => 2. Cr>3.0mg/dl or eGFR<15ml/min 3. Pregnant or possibly pregnant women and women on lactation 4. allergy to DPP-4 inhibitors 5. poor control,HbA1c(NGSP) 8.5% => and patients who were thought as inadequate for this study by doctor in charge

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c levels before and 24 weeks after drug administration and the influence of drug administration on renal function, liver function, and fat.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026